Heart safety of asthma drug tezepelumab under scrutiny in massive study
NCT ID NCT06951867
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks over 16,000 teens and adults with severe asthma to see if the drug tezepelumab raises the risk of serious heart problems like heart attack, stroke, or heart-related death. Researchers will compare those taking tezepelumab to those on standard asthma treatments. The goal is to better understand the drug's heart safety in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tezepelumab (brand name TEZSPIRE)
What this could lead to
If it shows tezepelumab is safe for the heart, it could reassure patients and doctors that this asthma treatment does not increase cardiovascular risk.
What could go wrong
This is an observational study, not a controlled trial, so it can only suggest links, not prove cause and effect. Results may be influenced by other factors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Danish registries (access/analysis)
RECRUITINGCopenhagen, Denmark
Contact Email: •••••@•••••
-
French National Health Data System (SNDS)
RECRUITINGParis, France
Contact Email: •••••@•••••
-
Healthcare Integrated Research Database (HIRD)
RECRUITINGWilmington, Delaware, 19801, United States
-
Team Gesundheit GKV Claims data (SHI)
RECRUITINGBerlin, Germany
Contact Email: •••••@•••••